Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: Associated illnesses and prior corticosteroid therapy

Mayo Clinic Proceedings

Volumn 71, Issue 1, 1996, Pages 5-13

  Yale, Steven H ^a   Limper, Andrew H ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; RISK FACTOR;

EID: 0030061707     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/71.1.5     Document Type: Article

References (37)

1. Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. Pneumocystis carinii pneumonia in the United States: epidemiologic, diagnostic, and clinical features. Ann Intern Med 1974; 80:83-93
2. Peters SG, Prakash UBS. Pneumocystis carinii pneumonia: review of 53 cases. Am J Med 1987; 82:73-78
3. Hughes WT. Pneumocystis carinii pneumonia. N Engl J Med 1977; 297:1381-1383
4. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993; 17(Suppl 2):S416S422
5. Limper AH, Offord KP, Smith TF, Martin WJ II. Pneumocystis carinii pneumonia: differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989; 140:1204-1209
6. Murray JF, Mills J. Pulmonary infectious complications of human immunodeficiency virus infection. Part II. Am Rev Respir Dis 1990; 141:1582-1598
7. Safrin S. Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Semin Respir Infect 1993; 8:96-103
8. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100:663-671
9. Wächter RM, Luce JM, Safrin S, Berrios DC, Charlebois E, Scitovsky AA. Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure. JAMA 1995; 273:230-235
10. Montaner JS, Lawson LM, Levitt N, Beizberg A, Schechter MT, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 113:14-20
11. Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, et al. A controlled trial of early adjuvant treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323:1451-1457
12. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a double-blind, placebo-controlled trial. N Engl J Med 1990; 323:1444-1450
13. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992; 267:832-837
14. Walzer PD. Experimental models for Pneumocystis carinii infections. Lung Biol Health Dis 1984; 22:7-76
15. Rifkind D, Paris TD, Hill RB Jr. Pneumocystis carinii pneumonia: studies on the diagnosis and treatment. Ann Intern Med 1966; 65:943-956
16. Slivka A, Wen PY, Shea WM, Loeffler JS. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med 1993; 94:216-219
17. Mahan CT, Sale GE. Rapid methenamine silver stain for Pneumocystis and fungi. Arch Pathol Lab Med 1978; 102:351-352
18. Kim YK, Parulekar S, Yu PK, Pisani RJ, Smith TF, Anhalt JP. Evaluation of calcofluor white stain for detection of Pneumocystis carinii. Diagn Microbiol Infect Dis 1990; 13:307-310
19. Haynes RC Jr, Murad F. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of adrenocortical steroid biosynthesis. In: Oilman AG, Goodman LS, Oilman A, editors. Goodman and Oilman's The Pharmacologie Basis of Therapeutics. 6th ed. New York: Macmillan, 1980: 1466-1496
20. DeVita VT Jr, Goodell B, Hubbard S, Geelhoed GW, Young RC. Pneumocystis pneumonia in patients with cancer: clinical setting. Natl Cancer Inst Monogr 1976; 43:41-47
21. Masur H, Lane HC, Kovacs JA, Allegra CJ, Edman JC. Pneumocystis pneumonia: from bench to clinic. Ann Intern Med 1989; 111:813-826
22. Walzer PD, LaBine M, Redington TJ, Cushion MT. Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: relation to Pneumocystis carinii pneumonia. J Immunol 1984; 133:2502-2508
23. Siminski J, Kidd P, Phillips GD, Collins C, Raghu G. Reversed helper/suppressor T-lymphocyte ratio in bronchoalveolar lavage fluid from patients with breast cancer and Pneumocystis carinii pneumonia. Am Rev Respir Dis 1991 : 143:437-440
24. Shellito J, Suzara W, Blumenfeld W, Beck JM, Steger HJ, Ermak TH. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest 1990; 85:1686-1693
25. Masur H, Jones TC. The interaction in vitro of Pneumocystis carinii with macrophages and L-cells. J Exp Med 1978; 147:157-170
26. Von Behren LA, Pesanti EL. Uptake and degradation of Pneumocystis carinii by macrophages in vitro. Am Rev Respir Dis 1978; 118:1051-1059
27. Hidalgo HA, Helmke RJ, German VF, Mangos JA. Pneumocystis carinii induces an oxidative burst in alveolar macrophages. Infect Immun 1992; 60:1-7
28. Huffman OA, Standing JE, Limper AH. Pneumocystis carinii stimulates tumor necrosis factor-a release from alveolar macrophages through a -glucan-mediated mechanism. J Immunol 1993; 150:3932-3940
29. Castro M, Morgenthaler TI, Huffman OA, Standing JE, Rohrbach MS, Limper AH. Pneumocystis carinii induces the release of arachidonic acid and its metabolites from alveolar macrophages. Am J Respir Cell Mol Biol 1993; 9:73-81
30. U. S. Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients With Human Immunodeficiency Virus Infection. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1993; 6:46-55
31. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994; 120:932-944
32. Centers for Disease Control. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1992; 41 (No. RR-4): 111
33. Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He W, et al (for the NIAID AIDS Clinical Trials Group). A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332:693-699
34. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987:316:16271632
35. Kuller J, First MR, D'Achiardi R, Munda R. Pneumocystis carinii pneumonia in renal transplant recipients. Am J Nephrol 1982; 2:312-315
36. Kramer MR, Stoehr C, Lewiston NJ, Starnes VA, Theodore J. Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation-how effective and for how long? Transplantation 1992;53:586-589
37. Colombo JL, Sammut PH, Langnas AN, Shaw BW Jr. The spectrum of Pneumocystis carinii infection after liver transplantation in children. Transplantation 1992; 54:621624